Considering that IL-1 is involved in the development of SP-induced pulmonary fibrosis (Piguet et al., 1993), the suppression of pyroptosis by dasatinib may contribute to its anti-fibrotic efficacy. This evidence concerns the gene IL1A and pulmonary fibrosis.